title: Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
abstract: OBJECTIVE
  This analysis was conducted to compare the direct medical costs of treatment with darbepoetin alfa every 3 weeks (Q3W) and epoetin alfa every week (QW) in patients with chemotherapy-induced anaemia (CIA) from the payer's perspective.
  
  
  METHODS
  An analysis was conducted from a US health plan perspective to compare the annual budget impact for CIA with darbepoetin alfa Q3W and epoetin alfa QW over a 16-week treatment period. Dosing regimens were obtained from registration clinical trials.
  
  
  RESULTS
  Mean doses, including dose adjustments, were 375.6 microg Q3W for darbepoetin alfa and 43,187 U QW for epoetin alfa. Costs of medical resources included drug acquisition and administration costs. The base case analysis resulted in a per-patient budget impact of $8,544 and $8,667 for darbepoetin alfa and epoetin alfa, respectively. Per member per month cost was $0.90 for darbepoetin alfa and $0.91 for epoetin alfa, based on an estimate of 2,735 CIA patients in a health plan population of 2.17 million. The analysis was most sensitive to drug dose, treatment period and drug price.
  
  
  CONCLUSIONS
  Results suggest that per-patient direct medical costs of CIA treatment, when initiated at labelled starting doses, are comparable for darbepoetin alfa Q3W and epoetin alfa QW.
authors.affiliation: Georgetown University, Washington, DC 20007, USA. rjr29@georgetown.edu
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Rubin
authors.forename: John A
authors.initials: JA
authors.lastname: Glaspy
authors.forename: John L
authors.initials: JL
authors.lastname: Adams
authors.forename: Michael S
authors.initials: MS
authors.lastname: Mafilios
authors.forename: Sharon M
authors.initials: SM
authors.lastname: Wang
authors.forename: Hema N
authors.initials: HN
authors.lastname: Viswanathan
authors.forename: Joel D
authors.initials: JD
authors.lastname: Kallich
mesh_terms: D000740:Anemia / Q000139:chemically induced* / Q000188:drug therapy*; D002017:Budgets; D000068256:Darbepoetin alfa; D064420:Drug-Related Side Effects and Adverse Reactions; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics*; D005102:Health Expenditures; D006397:Hematinics / Q000008:administration & dosage / Q000191:economics*; D006801:Humans; D011994:Recombinant Proteins; D013660:Taxes; D014481:United States
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa